COCH

Envoy Medical Inc.
NASDAQHEALTHCAREMEDICAL DEVICES

Key Statistics

Market Cap
$54.59M
P/E Ratio
EPS
$-0.97
Beta
1.86
52W High
$1.89
52W Low
$0.36
50-Day MA
$0.69
200-Day MA
$0.73
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About Envoy Medical Inc.

Envoy Medical Corporation manufactures and markets an implantable hearing aid device. The company is headquartered in White Bear Lake, Minnesota.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)234,000
Gross Profit (TTM)-537,000
EBITDA$-22.62M
Operating Margin-15279.00%
Return on Equity0.00%
Return on Assets-71.30%
Revenue/Share (TTM)$0.01
Book Value$0.14
Price-to-Book5.61
Price-to-Sales (TTM)233.27
EV/Revenue148.94
EV/EBITDA-1.35
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)-15.20%
Shares Outstanding$77.02M
Float$38.09M
% Insiders40.50%
% Institutions22.89%

Historical Volatility

HV 10-Day
105.18%
HV 20-Day
83.55%
HV 30-Day
70.90%
HV 60-Day
64.15%
HV Rank

Volatility is currently expanding

Latest News

Envoy Medical Submits First Module of Modular Premarket Approval Application to the U.S. Food and Drug Administration for Breakthrough-Designated Device

Modular Regulatory Strategy Creates Defined Milestone Cadence, Enables Earlier FDA Engagement, and Supports Targeted Final Clinical Module Submission Planned for Q2 2027 White Bear Lake, Minnesota--(Newsfile Corp. - June 30, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the submission of the first module of its Modular Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for its FDA Breakthrough Device-designated product. The submission marks the first regulatory milestone in the Company's planned modular PMA strategy.

Newsfile Corp6/30/2026Neutral
Envoy Medical Terminates At-the-Market (ATM) Equity Facility

Termination Reflects Company's Confidence in Current Capital Position White Bear Lake, Minnesota--(Newsfile Corp. - June 25, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has formally terminated its at-the-market equity facility (the "ATM Facility"). The ATM Facility, under which the Company was previously authorized to offer and sell up to $15 million worth of shares of its common stock from time to time, has been terminated effective June 24, 2026.

Newsfile Corp6/25/2026Neutral
Envoy Medical to Present at Investor Conferences on June 25th

White Bear Lake, Minnesota--(Newsfile Corp. - June 18, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Virtual Life Sciences Investor Forum and the Biotech Webull Webinar Panel on June 25, 2026. Life Sciences Virtual Investor Forum Dates: June 24th & 25th Presentation Day and Time: Thursday, June 25, 2026, at 1:00 p.m.

Newsfile Corp6/18/2026Neutral
Envoy Medical to Present at Planet MicroCap Conference Las Vegas on June 16th-18th

White Bear Lake, Minnesota--(Newsfile Corp. - June 4, 2026) - Envoy Medical® Inc. (NASDAQ: COCH), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV. Planet MicroCap Las Vegas 2026Dates: June 16-18, 2026 Location: Bellagio Hotel & Casino, Las Vegas, NV Booth: #410 Presentation Day and Time: Wednesday, June 17, 2026, at 11:00 A.M.

Newsfile Corp6/4/2026Neutral
Envoy Medical Announces New Patents Expanding Intellectual Property Portfolio in Fully Implanted Hearing Technology

Australian and European Patent Offices Grant the Company Four Patents Relating to Key Innovations in Implantable System Design, Signal Analysis, and Battery Recharge Safety White Bear Lake, Minnesota--(Newsfile Corp. - May 20, 2026) - Envoy Medical® Inc. (NASDAQ: COCH), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of multiple patents across Australia and Europe, as well as the upcoming grant of an additional European patent, further expanding the Company's intellectual property portfolio and reinforcing its position in the cochlear implant industry. "As we continue advancing fully implanted hearing technology, protecting the innovation behind these systems remains a key priority for Envoy Medical," said Brent Lucas, CEO, Envoy Medical.

Newsfile Corp5/20/2026Neutral
Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant

Company Completes Historic Trial Enrollment, Secures Transformational Financing, and Sees Promising Early Clinical Data Presented at Industry Conferences White Bear Lake, Minnesota--(Newsfile Corp. - May 11, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported first quarter 2026 results and landmark achievements that advance the Company another step closer toward commercialization of its investigational Acclaim® cochlear implant. "The first quarter of 2026 marked a transformative period for Envoy Medical, highlighted by the completion of enrollment in our pivotal clinical trial and the successful execution of a significant financing," said Brent Lucas, Chief Executive Officer of Envoy Medical.

Newsfile Corp5/11/2026Neutral
Envoy Medical Highlights First Clinical Data Presentations from Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant

Positive Initial 6-Month Data from First 10 Patients and Improvements in Speech Understanding and Quality of Life Scores Presented; Additional Presentations Scheduled in Early May Details to be Discussed During Fireside Chat on April 29, 2026 at 4:30 pm ET White Bear Lake, Minnesota--(Newsfile Corp. - April 28, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the first podium presentations of clinical data from the first stage of its pivotal clinical study of the investigational Acclaim® cochlear implant, a first-of-its-kind, fully implanted cochlear implant system. The Company will host a Fireside Chat with Dr. Theodore McRackan, MD, MSCR and Dr. Elizabeth Camposeo, AuD from the Medical University of South Carolina (MUSC) on Wednesday April 29, 2026 at 4:30 pm ET to review the data and its clinical implications.

Newsfile Corp4/28/2026Neutral
Envoy Medical Appoints Chas McKhann to Board of Directors

Proven Med Tech Leader with an Established Track Record of Commercial Success and Optimizing Shareholder Value Leading to over $3.4 Billion in Successful Exits White Bear Lake, Minnesota--(Newsfile Corp. - April 16, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced the appointment of Chas McKhann, a seasoned medical technology executive with documented success, to its Board of Directors. Mr. McKhann is a well-known and respected med tech leader with extensive experience creating and executing commercialization plans that have scaled into high-growth companies creating significant shareholder value.

Newsfile Corp4/16/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026